COMPARATIVE TERATOLOGICAL STUDY OF STOBADIN IN-VIVO AND IN-VITRO

Stobadin (STO) is a prospective cardioprotective drug with antiarrhyth mic and antihypoxic effects on the myocardium. Single iv injections of stobadin administered to rats on days 3, 6, 9 or 12 of gestation at d oses of 2 and 6 mg/kg had no teratogenic effect. Slight foetal toxicit y was manifested by decreased foetal weight (day 3 of gestation, 6 mg/ kg) and increased incidence of delayed ossification of the skull (day 12 of gestation, 6 mg/kg). In vitro studies were performed on chick em bryos explanted at Hamburger and Hamilton (HH) stages 4-5 and cultivat ed in a medium with stobadin concentration ranging from 10(-3) to 10(- 8) mol/litre under standard conditions. Concentrations of 10(-3) and 1 0(-4) mol/litre were lethal. Embryos treated with concentrations from 10(-8) to 10(-5) mol/litre were comparable to those of the control gro up. The results of in vivo and in vitro tests showed that the antiarrh ythmic agent stobadin at concentrations up to the maximal iv therapeut ic dose had no overt effects on different developmental stages of the rat embryo and early chick embryogenesis.